ArticlePathogens (Basel, Switzerland)2021
Determinants of HIV-1 Late Presentation in Patients Followed in Europe.
Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Factors associated with late HIV diagnosis among adults living with HIV in Oman: a 32-year ambidirectional cohort study at a tertiary referral hospital.BMC infectious diseases · 2026Article
- Reevaluating late HIV diagnosis incorporating recent infection evidence: a population-based study in Southwest China (2020-2023).BMC infectious diseases · 2026Article
- Risk factors for late HIV diagnosis in England, 2015-2023.HIV medicine · 2026Article
- Factors influencing late HIV presentation in China: results from logistic regression and Bayesian network analyses.BMC infectious diseases · 2026Article
- HIV-1 late diagnosis in Cabo Verde: associated factors and implications for preventive strategies.Frontiers in epidemiology · 2026Article
- Late HIV diagnosis: trends, risk factors, and progress toward the 2025 target of <20% late diagnosis in 23 EU/EEA countries, 2022 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Are people with HIV at advanced disease stages being left behind? A global survey.HIV medicine · 2025Article
- Unveiling trends in late diagnosis among 22,504 people living with HIV in Hunan, China.Scientific reports · 2024Article
- Sociobehavioral Risk Factors and Clinical Implications of Late Presentation Among People Living with HIV in the Brazilian Amazon Region.AIDS and behavior · 2024Article
- Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain.Journal of community health · 2024Article
- High prevalence of late presentation with advanced HIV disease and its predictors among newly diagnosed patients in Kumasi, Ghana.BMC infectious diseases · 2024Article
- Has COVID-19 Changed the Incidence and Profile of Late Presenters for HIV Infection in Lodz, Polish Reference Centre, Poland?Journal of clinical medicine · 2024Article
- Article
- Determinants of HIV late presentation among men who have sex with men in Portugal (2014-2019): who's being left behind?Frontiers in public health · 2024Article
- Editorial: World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIV.Frontiers in public health · 2024Article
- Article
- Prevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review.Infection · 2023Review
- Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network.Journal of the International AIDS Society · 2023Article
- Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network).Tropical medicine and infectious disease · 2023Article
- HIV Late Presenters in Asia: Management and Public Health Challenges.AIDS research and treatment · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
To control the Human Immunodeficiency Virus (HIV) pandemic, the World Health Organization (WHO) set the 90-90-90 target to be reached by 2020. One major threat to those goals is late presentation, which is defined as an individual presenting a TCD4+ count lower than 350 cells/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.